Senseonics raises CGM revenue guidance after 120% Q2 growth
Senseonics Holdings has reported record second-quarter revenue of $14.5 million, a 120% year-on-year increase, and has raised its full-year 2026 revenue guidance to $62 million to $66 million, up from a prior range of $60 million to $64 million. The Maryland-based maker of implantable continuous glucose monitoring (CGM) systems also lifted its full-year gross margin guidance to 58–61%, from 55–58%, following a Q2 gross margin of approximately 59%.
The results mark the second consecutive quarter of accelerating performance since Senseonics took its US commercial operations in-house, having previously relied on distribution partner Ascensia Diabetes Care. US revenue in the quarter reached $12.6 million, up more than 150% year-on-year, with active prescribers increasing approximately 130% and direct-to-consumer sales now representing the company's largest source of new patients. European revenue of $1.9 million was comparatively subdued, reflecting timing delays in tender processes as the company completed its transition of commercial operations across Germany, Italy, Spain, and Sweden in June.
Eon Care and development programmes
A notable growth driver in the quarter was Eon Care, Senseonics' nurse-staffed insertion service for the Eversense sensor, which scaled past 90 nurses and handled approximately 40% of all insertion procedures. The company said it remains on track to reach its year-end target of 100 nurses. Because the Eversense device requires a clinician to implant and remove the sensor, in-house clinical support infrastructure is a meaningful differentiator from patch-based CGM competitors.
Research and development expenditure rose to $11.6 million in Q2 2026, from $7.7 million a year earlier, with spending directed at the Gemini next-generation sensor programme and the longer-term Freedom development programme. Tim Goodnow, President and Chief Executive of Senseonics, said the company is "not just growing the business" but "redefining what a CGM can be," characterising this as a strategic as well as a commercial inflection.
The company also reported strong uptake of the Eversense 365 device in combination with the twiist Automated Insulin Delivery system, a development that broadens the addressable patient population.
Market context and competitive positioning
The broader CGM market is dominated by Abbott Laboratories and Dexcom, both of which offer wearable patch-style sensors with replacement cycles of 10 to 15 days. Senseonics occupies a distinct niche with its fully implantable, 365-day sensor, a form factor that appeals to patients seeking minimal day-to-day device management. The competitive question has long been whether the procedural barrier to implantation would limit uptake; the Q2 data suggest that barrier is becoming less prohibitive as Eon Care reduces patient-side friction.
The strong top-line result comes alongside a widening net loss. Operating expenses rose sharply to $44.5 million in Q2 2026, from $17.4 million in Q2 2025, driven primarily by the commercial build-out and European integration costs. Net loss for the quarter was $36.7 million, or $0.63 per share. Cash and investments at 30 June stood at approximately $143 million, bolstered by roughly $90 million in equity proceeds and an expanded Hercules Capital credit facility of up to $140 million raised during the quarter. The balance sheet provides meaningful runway, though investors will weigh the pace of operating expense normalisation against the revenue trajectory as Senseonics moves into its seasonally stronger second half.